Quarter 3 results Eli Lilly reported a 54% increase in revenue in the third quarter, rising to $17.60 billion in 2025 from $11.439 billion in 2024, which the company largely credited to sales of Mounjaro and Zepbound, the company’s GLP-1 agonist weight-loss treatments. Mounjaro revenue saw a 109% increase in revenue from the third quarter… The post Eli Lilly announces Q3 results, $3 billion new site, plans for oral GLP-1 approval appeared first on Drug Discovery and Development.| Drug Discovery and Development